Prothena publishes corporate overview presentation on protein dysregulation disease pipeline

• Prothena highlighted late-stage pipeline focus on protein misfolding diseases, led by partnered Phase 3 programs prasinezumab in Parkinson’s disease and coramitug in ATTR cardiomyopathy.
• Prasinezumab Phase 3 PARAISO trial remains ongoing in about 900 early Parkinson’s patients on stable levodopa, with primary completion expected in 2029.
• Coramitug Phase 3 CLEOPATTRA trial remains ongoing, with Phase 3 enrollment milestone of USD 50 million achieved; primary completion expected in 2029.
• BMS-986446 (PRX005) in Alzheimer’s disease remains in Phase 2, with TargetTau-1 trial completion expected in 1H 2027; PRX019 completed Phase 1, with a potential USD 55 million milestone tied to a Bristol Myers Squibb decision by year-end 2026.
• Capital return plan includes up to USD 100 million share repurchase authorization through Dec. 31, 2026; company also flagged up to about USD 3 billion in aggregate downstream milestones across partnered programs, with sales royalties tied to prasinezumab, BMS-986446, and PRX019.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prothena Corporation plc published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.